HemoShear Names Vincent E. Aurentz as President
~HemoShear Expands Business Strategy and Initiates Its Own Drug Discovery~
Jun 11, 2015, 07:00 ET
CHARLOTTESVILLE, Va., June 11, 2015 /PRNewswire/ -- HemoShear, a privately held discovery stage biotechnology company, announced today that Vincent E. Aurentz, Chief Business Officer, has been named President of HemoShear. Mr. Aurentz will be responsible for leading HemoShear's scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities. He will continue to report directly to CEO and Chairman Jim Powers, and will also join HemoShear's Board of Managers.
"Vince joined HemoShear in July, 2013, and has been instrumental in the evolution of our business strategy," said Mr. Powers. "Importantly, he has led HemoShear's efforts to leverage our unique disease tissue models and scientific expertise to begin our own drug discovery programs that we believe will create tremendous value for our all stakeholders. I look forward to working closely with Vince as we implement HemoShear's vision to discover and develop drugs for patients who lack safe and effective treatments for metabolic, cardiovascular, inflammatory and rare diseases."
Mr. Aurentz's appointment will utilize his more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive. He spent almost nine years with Merck KGaA and Merck Serono where he was Executive Vice President, Portfolio Development and member of the Executive Management Board as well as Head of Global Business Development. He was also recently Executive Vice President at Quintiles.
"This is an exciting time at HemoShear as we expand our programs to include a major focus on drug discovery, applying our transformational platform, REVEAL-Tx™, to identify novel therapeutic targets and biomarkers," said Vince Aurentz. "I am pleased be part of the leadership that will further drive the vision of our co-founders, Drs. Brett Blackman and Brian Wamhoff, to profoundly impact human health by delivering important therapeutics to patients with high unmet need."
HemoShear is a biotechnology company with a transformational approach to understanding human disease biology driven by REVEAL-Tx™, our revolutionary discovery platform. REVEAL-Tx™ leads us to proprietary discoveries in metabolic, cardiovascular and inflammatory disorders.
At HemoShear Therapeutics, we believe that precision matters; better models of human disease lead to better drug targets and better therapies. We collaborate with leading pharmaceutical and biotechnology companies who share our passion to deeply understand human disease biology and profoundly impact human health. Our current drug discovery efforts are focused on organic acidemias, a group of rare genetic metabolic disorders, and nonalcoholic steatohepatitis (NASH). THINK HUMAN.
HemoShear's platform, REVEAL-Tx™, provides a unique and powerful lens to interrogate biological mechanisms of human disease at a level not possible until now. In recreating complex pathophysiological pathways, we can identify novel targets, biomarkers and create superior therapeutics. Our discovery approach is agnostic to therapeutic modality, which allows us to apply the optimal technology to accurately and directly impact the drivers of disease.
Share this article